Compliance and patching and atropine amblyopia treatments.
In the past 20 years, there has been a great advancement in knowledge pertaining to compliance with amblyopia treatments. The occlusion dose monitor introduced quantitative monitoring methods in patching, which sparked our initial understanding of the dose-response relationship for patching amblyopia treatment. This review focuses on current compliance knowledge and the impact it has on patching and atropine amblyopia treatment.
Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, United States. Electronic address: jingyun.wang@gmail.com.
Jingyun
J
Wang
D000550:Amblyopia / Q000503:physiopathology / Q000628:therapy*; D001285:Atropine / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D009184:Mydriatics / Q000627:therapeutic use*; D010349:Patient Compliance / Q000523:psychology; D012683:Sensory Deprivation / Q000502:physiology*; D014792:Visual Acuity / Q000502:physiology
D009184:Mydriatics; D001285:Atropine
Amblyopia; Atropine penalization; Children; Compliance; Occlusion; Patching